UK markets close in 25 minutes
  • FTSE 100

    6,414.80
    +80.96 (+1.28%)
     
  • FTSE 250

    19,745.32
    +162.97 (+0.83%)
     
  • AIM

    1,032.89
    -2.15 (-0.21%)
     
  • GBP/EUR

    1.1248
    -0.0004 (-0.04%)
     
  • GBP/USD

    1.3360
    +0.0038 (+0.28%)
     
  • BTC-GBP

    14,459.73
    +613.58 (+4.43%)
     
  • CMC Crypto 200

    382.29
    +12.54 (+3.39%)
     
  • S&P 500

    3,622.47
    +44.88 (+1.25%)
     
  • DOW

    29,982.62
    +391.35 (+1.32%)
     
  • CRUDE OIL

    44.95
    +1.89 (+4.39%)
     
  • GOLD FUTURES

    1,801.50
    -36.30 (-1.98%)
     
  • NIKKEI 225

    26,165.59
    +638.22 (+2.50%)
     
  • HANG SENG

    26,588.20
    +102.00 (+0.39%)
     
  • DAX

    13,294.73
    +167.76 (+1.28%)
     
  • CAC 40

    5,556.88
    +64.73 (+1.18%)
     

Pfizer CEO made $5.6 million stock sale on same day as COVID-19 vaccine update - filing

·1-min read
The Pfizer logo is seen at their UK commercial headquarters in Walton Oaks
The Pfizer logo is seen at their UK commercial headquarters in Walton Oaks

(Reuters) - Pfizer Inc <PFE.N> Chief Executive Officer Albert Bourla sold $5.56 million (4.21 million pounds) worth of company shares on Monday, the day the drugmaker said its COVID-19 vaccine was 90% effective based on interim trial results, a regulatory filing showed.

Bourla authorized the sale of the shares on Aug. 19, provided the stock was at least at a certain price, as part of a predetermined plan, the company said.

Bourla sold 132,508 shares at $41.94 per share, according to a Securities and Exchange Commission filing late Tuesday. (https://bit.ly/3eQ0RPV)

"The sale of these shares is part of Dr. Bourla's personal financial planning and a pre-established (10b5-1) plan, which allows, under SEC rules, major shareholders and insiders of exchange-listed corporations to trade a predetermined number of shares at a predetermined time," Pfizer said.

Pfizer said on Monday its experimental COVID-19 vaccine was more than 90% effective based on initial trial results, sending its shares higher along with the broader markets.

The company's shares rose as much as 15% to trade at session high of $41.99 on Monday, before closing up 7.7%. They were trading at 38.75 on Wednesday.

Pfizer and German partner BioNTech SE <22UAy.F> have said no serious safety concerns were found so far and expect to seek U.S. emergency use authorization this month, raising the chance of a regulatory decision as soon as December.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli and Shounak Dasgupta)